Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (ovarian stromal cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 24 Parkinson's papers of 2,306 | 0.58 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10962
Sealed predictions
- CPZ in dopamine neurons, braak-0.44 (p 0.240) → +0.60 (p 0.089)receipt 10969
Swarm cases
receipt 10969: CPZ in dopamine neurons, braak
- power
- full sample -0.07 (p 0.787, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.18 (p 0.471, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.493, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.06, sign flips 3; without severely affected donors -0.07 (p 0.787, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CPZ in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts